

## Press Release

### S Kant Healthcare Limited

June 02, 2018

### Rating Reaffirmed



<b>Total Bank Facilities Rated*</b>	Rs. 28.50 Cr.
<b>Short Term Rating</b>	ACUITÉ A2

\* Refer Annexure for details

### Rating Rationale

Acuité has reaffirmed short term rating of '**ACUITÉ A2**' (read as **ACUITÉ A two**) on the Rs. 28.50 crore bank facilities of S Kant Healthcare Limited. The outlook is '**Stable**'.

The Mumbai based S Kant Healthcare Limited (SKHL), incorporated in 1996, is part of S K Group established in 1932 by Mr Sevantilal K. Shah. SKHL is a closely held public limited company engaged in the manufacturing of anti-malarial drugs and active pharmaceutical ingredients (API). SKHL is primarily exports to USA, UK and African countries like Ghana, Tanzania and Nigeria among others. The day to day operations are managed by Mr. Bharat Shah and Mr. Samir Shah.

Established in 1932, the SK Group consists of S Kant Healthcare Limited (SKHL) and S K Age Export (SKAE). The group specialises in the business of pharmaceuticals. SKHL manufactures antimalarial drugs and active pharmaceutical ingredients (API) at Vapi, Gujarat. SKAE was established in 1990 by Mr. Bharat Shah and Mr. Samir Shah and is into trading and exporting of formulations and active pharmaceutical ingredients (API). The registered office is located at Worli, Mumbai.

The rating has been reaffirmed in view of group's healthy profitability, strong financial risk profile, sound liquidity position and comfortable working capital cycle. However, the ratings are constrained by the uneven revenues, regulatory risk in domestic and export market and susceptibility of profitability to volatility in raw material prices and forex rates.

### Key Rating Drivers

#### Strengths

##### • Comfortable financial risk profile :

The financial risk profile of S K Group is above average marked by net worth of Rs 52.36 Crore in FY2017 as against Rs 51.35 Crore in the preceding year. The net worth levels have been maintained despite withdrawal of capital amounting to Rs 7.51 Crore in FY2017 from SKAE. The gearing (debt to equity) remained comfortable at 0.59 percent as on March 31st, 2017 as compared to 0.52 percent as on March 31st, 2016. The total debt outstanding of the group consists of short term borrowings of Rs.18.78 Crore and unsecured loans from related parties of Rs 12.29 Crore as on March 31st 2017. Further, the short term borrowings comprise of loans from affiliates and group companies amounting to Rs 11.05 Crore with the remaining being bank borrowings. The group exhibits robust debt protection measures as reflected by interest coverage ratio (ICR) of 12.09 times and debt servicing coverage ratio of 9.11 times in FY2017. The net cash accrual to debt remained healthy at 0.81 times in FY2017 as against 0.90 times in FY2018. ACUITÉ believes that going forward the group will maintain healthy financial risk profile in absence of any debt led capital expenditure.

- **Healthy liquidity position:**

S K Group's liquidity position is comfortable with moderate average bank utilization (65~70 percent in the last 6 months ending April 2018) and healthy cash generation against no repayment obligations. The net cash accruals of the group stood at Rs. 25.24 Crores in FY2017 as against Rs. 23.89 Crores in the previous year. Further, the liquidity profile draws comfort from availability of liquid funds (unencumbered cash and bank balance of Rs 14.56 Crore in FY2017 as against 13.15 Crore in FY2016).

- **Long track record and experienced management :**

The group has an established track record of more than five decade in pharmaceutical industry. The promoters, Mr. Bharat Shah, Mr. Samir Shah and Mr. Lalit Shah are third generation entrepreneurs and have over two decades of experience in the pharmaceutical sector.

## **Weaknesses**

- **Uneven growth in revenue profile; decline in profitability**

The group registered healthy revenue growth of 19.06 percent in FY2017. The operating revenue increased to Rs 176.64 Crore in FY2017 from Rs 148.36 Crore in FY2016 mainly driven by expansion to new markets including Nigeria and European markets. However, the group's revenue registered a significant decline in FY2018 (provisional). SKHL (the manufacturing arm of SK Group) registered a revenue of Rs 137.08 Crore in FY2018 as against 139.13 Crore in FY2017. SKAE, the trading arm of SK Group, registered significant decline from Rs 83.69 Crore in FY2017 to Rs 59.56 Crore in FY2018. This was mainly on account of rollout of GST and inability to execute pending orders.

The net profit margins declined to 21.08 percent in FY2017 as against 26.86 percent in FY2016 due to increase in raw material cost and selling expense incurred. The net profit margins moderated to 11.66 percent in FY2017 as against 12.80 percent in FY2016. Going forward, the group's ability to scale up operations sustainably and maintain its profitability would be a key rating sensitivity.

- **Susceptibility of profitability to volatility in raw material prices and regulatory risk**

The group's profitability is susceptible to volatility in raw material prices and foreign exchange rates. The group exports over 90 percent of its output to Denmark, Ghana, Uganda, and Singapore among others. However the same is mitigated by selectively hedging its risk exposure. Further, the group is also exposed to the regulatory risk associated with export of medical drugs to USA, UK and African countries among other.

## **Analytical Approach**

ACUITÉ has taken a consolidated view of S Kant Health Care Private Limited (SKHL) and S K Age Export (SKAE) referred to as the S K Group. This is due to the strong operational and financial linkages between the two entities and common management.

## **Outlook: Not Applicable**

## **About the Group**

Established in 1932, the SK Group consists of S Kant Healthcare Limited (SKHL) and S K Age Export (SKAE). The group specialises in the business of pharmaceuticals. SKHL manufactures antimalarial drugs and active pharmaceutical ingredients (API) at Vapi, Gujarat. SKAE was established in 1990 by Mr. Bharat Shah and Mr. Samir Shah and is into trading and exporting of formulations and active pharmaceutical ingredients (API).

## About the Rated Entity - Key Financials

	Unit	FY17 (Actual)	FY16 (Actual)	FY15 (Actual)
Operating Income	Rs. Cr.	176.64	148.36	156.60
EBITDA	Rs. Cr.	37.23	39.84	39.20
PAT	Rs. Cr.	20.60	19.00	17.82
EBITDA Margin	(%)	21.08	26.86	25.03
PAT Margin	(%)	11.66	12.80	11.38
ROCE	(%)	40.44	46.80	94.36
Total Debt/Tangible Net Worth	Times	0.59	0.52	0.66
PBDIT/Interest	Times	12.09	6.06	4.73
Total Debt/PBDIT	Times	0.83	0.66	0.72
Gross Current Assets (Days)	Days	178	203	196

## Status of non-cooperation with previous CRA (if applicable)

None

## Any other information

None

## Applicable Criteria

- Default Recognition - <https://www.acuite.in/criteria-default.htm>
- Manufacturing Entities - <https://www.acuite.in/criteria-manufacturing.htm>
- Financial Ratios And Adjustments - <https://www.acuite.in/criteria-fin-ratios.htm>

## Note on complexity levels of the rated instrument

<https://www.acuite.in/criteria-complexity-levels.htm>

## Rating History (Upto last three years)

Date	Name of Instrument / Facilities	Term	Amount (Rs. Cr.)	Ratings/Outlook
02-Mar-2017	Bills Discounting	Short Term	8.00	ACUITE A2
	Bills Discounting	Short Term	11.00	ACUITE A2
	Bank Guarantee	Short Term	3.50	ACUITE A2
	Letter of Credit	Short Term	5.00	ACUITE A2
	Bank Guarantee	Short Term	1.00	ACUITE A2

## \*Annexure – Details of instruments rated

Name of the Facilities	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. Cr.)	Ratings/Outlook
------------------------	------------------	-------------	---------------	-----------------------------	-----------------

Bills Discounting	Not Applicable	Not Applicable	Not Applicable	8.00	ACUITÉ A2
Bills Discounting	Not Applicable	Not Applicable	Not Applicable	11.00	ACUITÉ A2
Bank guarantee/Letter of Guarantee	Not Applicable	Not Applicable	Not Applicable	3.50	ACUITÉ A2
Letter of credit	Not Applicable	Not Applicable	Not Applicable	6.00	ACUITÉ A2

## Contacts

Analytical	Rating Desk
<p>Suman Chowdhury President - Rating Operations Tel: 022-67141107 <a href="mailto:suman.chowdhury@acuite.in">suman.chowdhury@acuite.in</a></p> <p>Swati Banthia Analyst - Rating Operations Tel: 022-67141116 <a href="mailto:swati.banthia@acuite.in">swati.banthia@acuite.in</a></p>	<p>Varsha Bist Manager - Rating Desk Tel: 022-67141160 <a href="mailto:varsha.bist@acuite.in">varsha.bist@acuite.in</a></p>

**Disclaimer:** An Acuite rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. Acuite ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, Acuite, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. Acuite is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. Acuite ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website ([www.acuite.in](http://www.acuite.in)) for the latest information on any instrument rated by Acuite.